Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (201-210 of 302) with videos related to

Pageof 31
Sort By:
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Journal of Diabetes|October 21, 2014
Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitorMukul R Jain, Amit A Joharapurkar, Rajesh H Bahekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, et al.
Cancer Therapy|January 9, 2009
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumorsAndrew J Lepisto, Arthur J Moser, Herbert Zeh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursJeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Investigational New Drugs|July 21, 2017
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumorsGlen J Weiss, Gayle Jameson, Daniel D Von Hoff, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II doseKyle D Holen, Chandra P Belani, George Wilding, et al.
Immunotherapy|September 7, 2018
Novel immunotherapy strategies for hepatobiliary cancersThomas T DeLeon, Yumei Zhou, Bolni M Nagalo, et al.
Case Reports in Gastroenterology|December 7, 2016
Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature ReviewJames M Chang, Nitin N Katariya, Dora M Lam-Himlin, et al.
Pageof 31

Showing results (201-210 of 302) with videos related to

Sort By:
Pageof 31
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Journal of Diabetes|October 21, 2014
Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitorMukul R Jain, Amit A Joharapurkar, Rajesh H Bahekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumorsRamesh K Ramanathan, D Lynn Kirkpatrick, Chandra P Belani, et al.
Cancer Therapy|January 9, 2009
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumorsAndrew J Lepisto, Arthur J Moser, Herbert Zeh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyHoward S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursJeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Investigational New Drugs|July 21, 2017
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumorsGlen J Weiss, Gayle Jameson, Daniel D Von Hoff, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II doseKyle D Holen, Chandra P Belani, George Wilding, et al.
Immunotherapy|September 7, 2018
Novel immunotherapy strategies for hepatobiliary cancersThomas T DeLeon, Yumei Zhou, Bolni M Nagalo, et al.
Case Reports in Gastroenterology|December 7, 2016
Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature ReviewJames M Chang, Nitin N Katariya, Dora M Lam-Himlin, et al.
Pageof 31